Introduction
The route by which a research peptide is administered fundamentally determines how much of the compound reaches its target, how quickly it does so, and for how long it remains active. This guide compares the primary administration routes used in research peptide protocols and explains the practical considerations for each.
Subcutaneous Administration
Subcutaneous (SC) injection — delivery into the tissue layer just beneath the skin — is the most common route for research peptides and many clinical peptide therapeutics. The subcutaneous space contains a network of blood and lymphatic capillaries. After injection, peptides are absorbed into these capillaries, typically producing peak plasma concentrations within 15 to 60 minutes depending on the peptide and injection site. Bioavailability following SC injection is generally 70 to 100% for most research peptides. SC injection is practical, reproducible, and suitable for repeated dosing in animal research models. Common SC injection sites in rodent research are the scruff (back of neck) or flank.
Intravenous Administration
Intravenous (IV) injection delivers the compound directly into the bloodstream, providing 100% bioavailability by definition and producing near-immediate peak plasma concentrations. IV administration is used in research when precise timing of peptide exposure is critical — for example, when measuring acute GH responses or studying receptor kinetics. It is technically more demanding than SC injection, requires sterile, isotonic, particulate-free formulations, and is less practical for repeated dosing in chronic animal studies. Tail vein injection is the standard IV route in rodent models.
Intramuscular Administration
Intramuscular (IM) injection deposits the compound into skeletal muscle tissue, where absorption into local vasculature produces plasma concentrations comparable to SC delivery. Absorption rate may be slightly faster than SC due to higher muscle vascularity. IM is less commonly used for research peptides than SC but is appropriate when SC sites are limited or specific protocols call for it.
Intranasal Administration
Intranasal delivery exploits two distinct pathways. The olfactory pathway: olfactory neurons in the nasal epithelium extend axons through the cribriform plate directly into the olfactory bulb, providing an anatomical conduit for molecule transport from nose to brain that bypasses the blood-brain barrier. The trigeminal pathway: trigeminal nerve branches in the nasal mucosa similarly provide a neural conduit to brainstem regions. These pathways enable direct nose-to-brain delivery of neuropeptides at concentrations that may not be achievable through systemic administration. Semax and Selank are clinically studied via intranasal routes in Russia specifically for CNS delivery. Systemic bioavailability via intranasal delivery is moderate — some peptide enters systemic circulation through nasal mucosal absorption.
Intraperitoneal Administration
Intraperitoneal (IP) injection into the abdominal cavity is widely used in rodent research as a convenient systemic administration route that avoids the technical demands of IV injection while providing more consistent delivery than SC injection in some models. Absorption occurs through the peritoneal vasculature and may include first-pass hepatic processing for some compounds. IP is common in pharmacology research but less representative of clinically relevant administration routes.
Oral Administration
Oral administration is impractical for most research peptides due to GI proteolysis and poor intestinal permeability. Exceptions include modified peptides engineered for oral stability (like Semaglutide’s oral tablet formulation), unusually stable peptides like BPC-157 in GI models, and very small peptide-like molecules like Dihexa. Oral routes are used in specific research contexts when GI stability is the research variable being studied.
Conclusion
The choice of administration route is a fundamental research design decision that determines bioavailability, pharmacokinetics, and which organ systems are primarily exposed to the peptide. Subcutaneous injection is the practical standard for most research protocols. IV is used for acute mechanistic studies. Intranasal is selected specifically for CNS delivery research. Matching the route to the research question is essential for generating valid, interpretable data.